April 25, 2018
TOKYO, JAPAN - April 25, 2018 - Terumo Corporation (TSE: 4543) announced today that it acquired CE marking for the Ultimaster™ Tansei™ drug eluting stent (DES). Looking ahead, Terumo will begin sales of the product in Europe in May 2018. On January 24, 2018, Terumo received approval to manufacture and sell Ultimaster Tansei in Japan, and it plans to release the product in the second half of fiscal 2018.
For the Ultimaster Tansei, Terumo inherited the same stent, drug, polymer, and coating methods used for its predecessor, the Ultimaster DES, which was launched in 2014, while making improvements to the tip and shaft in order to facilitate stent delivery in complex lesions. Terumo aimed to enhance the product's usability and make it easier to navigate the stent through the blood vessels by creating a tip with a structure using highly durable yet still flexible materials, and by designing the shaft to have highly kink-resistance, providing exceptional pushability.
Available in a wide range of sizes, Ultimaster Tansei enables a broad variety of treatment options. Terumo will offer a total of 54 size lineup with stent diameter ranging from 2.25 to 4.0 mm, and lengths from 9 to 38 mm in addition to the standard length of 21 mm. Accordingly, the new product will facilitate an extensive range of treatments for complex lesions.
Terumo has been strategically developing the DES under its Mid- to Long-term Growth Strategy. Following the release of the new Ultimaster Tansei, Terumo plans to launch more products with improved stent designs as metal DES in the Ultimaster series, with the goals of securing the number-one share of the DES market in Japan and doubling its market share in Europe and emerging countries. While offering optimal therapeutic alternatives to healthcare professionals, Terumo will work to contribute to improving the quality of life of patients worldwide in the future.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the health care market, and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.